Report Summary
Eternity Insights can provide a deep dive research report highlighting the market and competitive in-telligence across the key segments of the market. The report also considers the impact of COVID-19 on the global Intravenous (IV) Iron Drugs market. The report considers 2018-2020 historic period, 2021 as base year, and 2022-2028 as forecast period. The report includes quantitative analysis of the market supported by the mar-ket drivers, challenges, and trends to accurately map the market scenario and competition.
Intravenous (IV) Iron Drugs market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through the primary research and expert insights. Eternity Insights also uses paid data bases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.
To learn more about this report
Key Research Highlights: Market Drivers
The Intravenous (IV) Iron Drugs market is estimated to expand at a considerable growth rate during the forecast period ow-ing to increasing prevalence of venous diseases and increasing new product approvals to cater this demand. Rise in the awareness about the diseases, increasing importance of early diagnosis, and growing spending on chronic diseases are poised to boost the market growth. Moreover, the key players in the market are investing in research and development of technologically advanced products leading to increased utilization of the Intravenous (IV) Iron Drugs products across developed and developing countries of the world.
Key Research Highlights: Market Restrains
Limited awareness about the diseases, high cost of products, low economical condition, and lack of favorable insurance systems restricts the adoption of Intravenous (IV) Iron Drugs products across developing regions of the globe. However, launch of new products with low cost and increasing efforts for market penetration in these regions can offer lucrative growth opportunities for the players in the Intravenous (IV) Iron Drugs market.
To learn more about this report
Key Research Highlights: Trends
Increasing research and development spending on Intravenous (IV) Iron Drugs development has been the leading industry trend of Intravenous (IV) Iron Drugs market
The leading players in the market are focused on developing products which are cost effective and high quality to tap the huge unaddressed opportunities in the developing regions. This can be wit-nessed from the increasing spending on research and development and growing number of new product approvals.
Global Intravenous (IV) Iron Drugs Market Size, 2018-2028 (USD MILLION)
To learn more about this report
Market Segmentation
| Report Attributes |
Details |
| The market size value in 2021 |
USD XX.XX Million |
| CAGR (2021 - 2028) |
XX.XX % |
| The Revenue forecast in 2028 |
USD XX.XX Million |
| Base year for estimation |
2021 |
| Historical data |
2018-2019 |
| Forecast period |
2022-2028 |
| Quantitative units |
- Revenue in USD Million
- CAGR from 2021 to 2028
|
| Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered |
By Type Outlook, Application Outlook, Regional Outlook |
| By Type Outlook |
Ferric Carboxymaltose,Iron Sucrose,Iron Dextran,Others |
| By Application Outlook |
Nephrology,Gynecology & Obstetrics,Gastroenterology,Oncology,Cardiology,Others |
| Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Country scope |
U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey |
| Key companies profiled |
Sanofi,Allergan,AMAG Pharmaceuticals,Dalichi Sankyo,Luitpold Pharmaceuticals,Pharmacosmos,Takeda Pharmaceutical |
| Customization Available |
Yes, the report can be tailored to meet your specific requirements. |
Key Market Players
- Sanofi
- Allergan
- AMAG Pharmaceuticals
- Dalichi Sankyo
- Luitpold Pharmaceuticals
- Pharmacosmos
- Takeda Pharmaceutical
Intravenous (IV) Iron Drugs Market, By Type
- Ferric Carboxymaltose
- Iron Sucrose
- Iron Dextran
- Others
Intravenous (IV) Iron Drugs Market, By Application
- Nephrology
- Gynecology & Obstetrics
- Gastroenterology
- Oncology
- Cardiology
- Others
Key Benefits To The Stake Holders
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) and volume (Tons) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Table Of Contents
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Major Manufacturers Covered in This Report
1.3 Market Segment by Type
1.3.1 Global Intravenous (IV) Iron Drugs Market Size Growth Rate by Type (2019-2025)
1.3.2 Ferric Carboxymaltose
1.3.3 Iron Sucrose
1.3.4 Iron Dextran
1.3.5 Others
1.4 Market Segment by Application
1.4.1 Global Intravenous (IV) Iron Drugs Market Share by Application (2019-2025)
1.4.2 Nephrology
1.4.3 Gynecology & Obstetrics
1.4.4 Gastroenterology
1.4.5 Oncology
1.4.6 Cardiology
1.4.7 Others
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Intravenous (IV) Iron Drugs Market Size
2.1.1 Global Intravenous (IV) Iron Drugs Revenue 2014-2025
2.1.2 Global Intravenous (IV) Iron Drugs Sales 2014-2025
2.2 Intravenous (IV) Iron Drugs Growth Rate by Regions
2.2.1 Global Intravenous (IV) Iron Drugs Sales by Regions 2014-2019
2.2.2 Global Intravenous (IV) Iron Drugs Revenue by Regions 2014-2019
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
3 Market Share by Manufacturers
3.1 Intravenous (IV) Iron Drugs Sales by Manufacturers
3.1.1 Intravenous (IV) Iron Drugs Sales by Manufacturers 2014-2019
3.1.2 Intravenous (IV) Iron Drugs Sales Market Share by Manufacturers 2014-2019
3.2 Revenue by Manufacturers
3.2.1 Intravenous (IV) Iron Drugs Revenue by Manufacturers (2014-2019)
3.2.2 Intravenous (IV) Iron Drugs Revenue Share by Manufacturers (2014-2019)
3.2.3 Global Intravenous (IV) Iron Drugs Market Concentration Ratio (CR5 and HHI)
3.3 Intravenous (IV) Iron Drugs Price by Manufacturers
3.4 Key Manufacturers Intravenous (IV) Iron Drugs Plants/Factories Distribution and Area Served
3.5 Date of Key Manufacturers Enter into Intravenous (IV) Iron Drugs Market
3.6 Key Manufacturers Intravenous (IV) Iron Drugs Product Offered
3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Sales and Revenue for Each Type
4.1.1 Ferric Carboxymaltose Sales and Revenue (2014-2019)
4.1.2 Iron Sucrose Sales and Revenue (2014-2019)
4.1.3 Iron Dextran Sales and Revenue (2014-2019)
4.1.4 Others Sales and Revenue (2014-2019)
4.2 Global Intravenous (IV) Iron Drugs Sales Market Share by Type
4.3 Global Intravenous (IV) Iron Drugs Revenue Market Share by Type
4.4 Intravenous (IV) Iron Drugs Price by Type
5 Market Size by Application
5.1 Overview
5.2 Global Intravenous (IV) Iron Drugs Sales by Application
6 United States
6.1 United States Intravenous (IV) Iron Drugs Breakdown Data by Company
6.2 United States Intravenous (IV) Iron Drugs Breakdown Data by Type
6.3 United States Intravenous (IV) Iron Drugs Breakdown Data by Application
7 European Union
7.1 European Union Intravenous (IV) Iron Drugs Breakdown Data by Company
7.2 European Union Intravenous (IV) Iron Drugs Breakdown Data by Type
7.3 European Union Intravenous (IV) Iron Drugs Breakdown Data by Application
8 China
8.1 China Intravenous (IV) Iron Drugs Breakdown Data by Company
8.2 China Intravenous (IV) Iron Drugs Breakdown Data by Type
8.3 China Intravenous (IV) Iron Drugs Breakdown Data by Application
9 Rest of World
9.1 Rest of World Intravenous (IV) Iron Drugs Breakdown Data by Company
9.2 Rest of World Intravenous (IV) Iron Drugs Breakdown Data by Type
9.3 Rest of World Intravenous (IV) Iron Drugs Breakdown Data by Application
9.4 Rest of World Intravenous (IV) Iron Drugs Breakdown Data by Countries
9.4.1 Rest of World Intravenous (IV) Iron Drugs Sales by Countries
9.4.2 Rest of World Intravenous (IV) Iron Drugs Revenue by Countries
9.4.3 Japan
9.4.4 Korea
9.4.5 India
9.4.6 Southeast Asia
10 Company Profiles
10.1 Sanofi
10.1.1 Sanofi Company Details
10.1.2 Company Description and Business Overview
10.1.3 Sales, Revenue and Market Share of Intravenous (IV) Iron Drugs
10.1.4 Intravenous (IV) Iron Drugs Product Introduction
10.1.5 Sanofi Recent Development
10.2 Allergan
10.2.1 Allergan Company Details
10.2.2 Company Description and Business Overview
10.2.3 Sales, Revenue and Market Share of Intravenous (IV) Iron Drugs
10.2.4 Intravenous (IV) Iron Drugs Product Introduction
10.2.5 Allergan Recent Development
10.3 AMAG Pharmaceuticals
10.3.1 AMAG Pharmaceuticals Company Details
10.3.2 Company Description and Business Overview
10.3.3 Sales, Revenue and Market Share of Intravenous (IV) Iron Drugs
10.3.4 Intravenous (IV) Iron Drugs Product Introduction
10.3.5 AMAG Pharmaceuticals Recent Development
10.4 Dalichi Sankyo
10.4.1 Dalichi Sankyo Company Details
10.4.2 Company Description and Business Overview
10.4.3 Sales, Revenue and Market Share of Intravenous (IV) Iron Drugs
10.4.4 Intravenous (IV) Iron Drugs Product Introduction
10.4.5 Dalichi Sankyo Recent Development
10.5 Luitpold Pharmaceuticals
10.5.1 Luitpold Pharmaceuticals Company Details
10.5.2 Company Description and Business Overview
10.5.3 Sales, Revenue and Market Share of Intravenous (IV) Iron Drugs
10.5.4 Intravenous (IV) Iron Drugs Product Introduction
10.5.5 Luitpold Pharmaceuticals Recent Development
10.6 Pharmacosmos
10.6.1 Pharmacosmos Company Details
10.6.2 Company Description and Business Overview
10.6.3 Sales, Revenue and Market Share of Intravenous (IV) Iron Drugs
10.6.4 Intravenous (IV) Iron Drugs Product Introduction
10.6.5 Pharmacosmos Recent Development
10.7 Takeda Pharmaceutical
10.7.1 Takeda Pharmaceutical Company Details
10.7.2 Company Description and Business Overview
10.7.3 Sales, Revenue and Market Share of Intravenous (IV) Iron Drugs
10.7.4 Intravenous (IV) Iron Drugs Product Introduction
10.7.5 Takeda Pharmaceutical Recent Development
11 Value Chain and Sales Channels Analysis
11.1 Value Chain Analysis
11.2 Sales Channels Analysis
11.2.1 Intravenous (IV) Iron Drugs Sales Channels
11.2.2 Intravenous (IV) Iron Drugs Distributors
11.3 Intravenous (IV) Iron Drugs Customers
12 Market Forecast
12.1 Global Intravenous (IV) Iron Drugs Sales and Revenue Forecast 2019-2025
12.2 Global Intravenous (IV) Iron Drugs Sales Forecast by Type
12.3 Global Intravenous (IV) Iron Drugs Sales Forecast by Application
12.4 Intravenous (IV) Iron Drugs Forecast by Regions
12.4.1 Global Intravenous (IV) Iron Drugs Sales Forecast by Regions 2019-2025
12.4.2 Global Intravenous (IV) Iron Drugs Revenue Forecast by Regions 2019-2025
12.5 United States Market Forecast
12.6 European Union Market Forecast
12.7 China Market Forecast
12.8 Rest of World
12.8.1 Japan
12.8.2 Korea
12.8.3 India
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
